Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $22 to $18.
Questions Surround Vertex/CRISPR’s Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next
